Nanobiotix/$NBTX

1D1W1MYTD1Y5YMAX

About Nanobiotix

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Ticker
$NBTX
Sector
Health
Primary listing
NASDAQ
Employees
100
Headquarters
Paris, France
Website
www.nanobiotix.com

Nanobiotix Metrics

BasicAdvanced
$1.8B
-
-$0.58
0.58
-

What the Analysts think about Nanobiotix

Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Analyst projections of the future price of Nanobiotix stock.

Bulls say / Bears say

Part 1 of the Phase 2 CONVERGE trial showed an objective response rate of 85.7%, complete response rate of 57.1%, and disease control rate of 100% in seven patients, underscoring potential efficacy of JNJ-1900 (NBTXR3) in NSCLC. (SEC Form 6-K)
Nanobiotix narrowed its FY 2025 net loss to €24.0 million and extended its cash runway into early 2028 via a $71 million royalty financing agreement with HealthCare Royalty, supporting continued development across oncology platforms. (MarketScreener)
The global offering closed on May 26, 2026 raised approximately $100 million (€86.1 million) in gross proceeds, bolstering resources for ongoing development of JNJ-1900 (NBTXR3) and other platforms with funding through 2029. (SEC Filing)
CONVERGE Part 1 data derive from only seven patients, and Nanobiotix cautions these preliminary results should not be relied upon as predictive of future performance. (SEC Form 6-K)
Despite narrowing losses, Nanobiotix remains unprofitable, reporting a €24.0 million net loss in FY 2025, underscoring ongoing reliance on external financing and potential for shareholder dilution. (MarketScreener)
The FDA-accepted protocol amendment for the Phase 3 NANORAY-312 study eliminated an interim analysis and deferred final analysis, potentially reducing near-term data visibility for investors. (SEC Form 6-K)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.

Nanobiotix Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Nanobiotix Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.